Gender-specific differences in clinical outcome of primary prevention implantable cardioverter defibrillator recipients

    loading  Checking for direct PDF access through Ovid

Abstract

Objective

To assess differences in clinical outcome of implantable cardioverter-defibrillator (ICD) treatment in men and women.

Design

Prospective cohort study.

Setting

University Medical Center.

Patients

1946 primary prevention ICD recipients (1528 (79%) men and 418 (21%) women). Patients with congenital heart disease were excluded for this analysis.

Main outcome measures

All-cause mortality, ICD therapy (antitachycardia pacing and shock) and ICD shock.

Results

During a median follow-up of 3.3 years (25th–75th percentile 1.4–5.4), 387 (25%) men and 76 (18%) women died. The estimated 5-year cumulative incidence for all-cause mortality was 20% (95% CI 18% to 23%) for men and 14% (95% CI 9% to 19%) for women (log rank p<0.01). After adjustment for potential confounding covariates all-cause mortality was lower in women (HR 0.65; 95% CI 0.49 to 0.84; p<0.01). The 5-year cumulative incidence for appropriate therapy in men was 24% (95% CI 21% to 28%) as compared with 20% (95% CI 14% to 26%) in women (log rank p=0.07). After adjustment, a non-significant trend remained (HR 0.82; 95% CI 0.64 to 1.06; p=0.13).

Conclusions

In clinical practice, 21% of primary prevention ICD recipients are women. Women have lower mortality and tend to experience less appropriate ICD therapy as compared with their male peers.

Related Topics

    loading  Loading Related Articles